A call for reminder before it’s too late atypical endometrial hyperplasia and concurrent cancer in reproductive age women
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20250535Keywords:
Endometrial hyperplasia, Endometrial adenocarcinoma, Young women, Risk factors, ManagementAbstract
Endometrial hyperplasia is a hyper proliferation of endometrial cells predominantly of stromal glandular components under estrogen influence. This is a premalignant lesion which concomitant with endometrial carcinoma in 40% of cases. Major risk factors are estrogen predominant states such as nulliparity, early menarche, late menopause, obesity, infertility, polycystic ovarian syndromes, estrogen producing tumours. Prolonged use of COCs, tamoxifen also plays a role in endometrial hyperplasia leading to concurrent endometrial carcinoma in reproductive age women. Pointing towards pathology endometrial carcinoma diagnosed at an earlier age are mostly of low grades with lower stage and good clinical outcomes. With this review we emphasize the need of endometrial sampling or fractional curettage in all young women with altered menstrual flow with suspicious of increased endometrial thickening before starting any medications.
Metrics
References
Raju DS, Raveendran RC, Manivannan A. Prevalence of Coexisting Endometrial Carcinoma in Patients with Preoperative Diagnosis of Endometrial Hyperplasia with Atypia. J Evid Based Med Healthc. 2020;7(52):3180-4. DOI: https://doi.org/10.18410/jebmh/2020/647
Bharatnur S, Kustagi P, Krishnamohan D. Endometrial Carcinoma in a Young Woman: “30 is Not Immune.” J Obstet Gynecol India. 2011;61(6):686-8. DOI: https://doi.org/10.1007/s13224-011-0091-y
Lekhi A, Manchanda R, Jain N, Chithra S, Kausar H. Endometrial carcinoma in young women: management options and its review. Int J Reprod Contracept Obstet Gynecol. 2016;944-7. DOI: https://doi.org/10.18203/2320-1770.ijrcog20160674
Agarwal S, Melgandi W, Sonkar DR, Ansari FA, Arora S, Rathi AK, et al. Epidemiological characteristics of endometrial cancer patients treated at a tertiary health center in National Capital Territory of India. J Cancer Res Ther. 2023;19(2):452-6. DOI: https://doi.org/10.4103/jcrt.jcrt_2029_21
Henderson I, Black N, Khattak H, UKARCOG Working Group Authors, Gupta JK, Rimmer MP. Diagnosis and management of endometrial hyperplasia: A UK national audit of adherence to national guidance 2012–2020. Stock SJ, editor. PLOS Med. 2024;21(2):e1004346. DOI: https://doi.org/10.1371/journal.pmed.1004346
Shree Ca P, Garg M, Bhati P, Sheejamol VS. Should we prioritise proper surgical staging for patients with Atypical endometrial hyperplasia (AEH)? Experience from a single-institution tertiary care oncology centre. Eur J Obstet Gynecol Reprod Biol. 2024;303:1-8. DOI: https://doi.org/10.1016/j.ejogrb.2024.09.044
Giannella L, Piva F, Delli Carpini G, Di Giuseppe J, Grelloni C, Giulietti M, et al. Concurrent Endometrial Cancer in Women with Atypical Endometrial Hyperplasia: What Is the Predictive Value of Patient Characteristics? Cancers. 2023;16(1):172. DOI: https://doi.org/10.3390/cancers16010172
Mak KS, Huang KG, Kuo HH. An incidental diagnosis of endometrial cancer in a young and underweight female with isolated symptom of amenorrhea. Taiwan J Obstet Gynecol. 2022;61(2):399-401. DOI: https://doi.org/10.1016/j.tjog.2022.02.039
Berek JS. Berek & Novak’s Gynecology. 16th edition. Philadelphia: Wolters Kluwer. 2020.
Royal College of Obstetricians & Gynaecologists. Management of Endometrial Hyperplasia: Green-top Guideline No. 67. 2016. Available at: https://www.rcog.org.uk/guidance/browseallguidance/green-top-guidelines/management-of-endometrial-hyperplasia-green-top-guideline-no-67/. Accessed on 24 October 2024.
Downloads
Published
How to Cite
Issue
Section
